Related Experiment Video
Updated: Aug 3, 2025
06:03
Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
Published on: September 20, 2024
1.3K
Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized
Angela R Branche1, Nadine G Rouphael2, Cecilia Losada2
1University of Rochester VTEU, Rochester, NY.
Medrxiv : the Preprint Server for Health Sciences
|April 10, 2023
Abstract:
In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent SARS-CoV-2 mRNA vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wildtype spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.
